The biopharmaceutical industry is undergoing a transformative period, driven by rapid advancements in artificial intelligence (AI). As we approach 2025, the integration of AI into regulatory compliance, particularly in biotherapeutic cell line approvals, is poised to revolutionize the sector. This article explores how AI is streamlining these processes, benefiting a wide range of stakeholders...